1250.1 - Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)

Page last updated: 12 October 2016

Application Detail



Description of Medical Service

ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.

Description of Medical Condition

ALK-positive advanced NSCLC.

Reason for Application


Medical Service Type


Previous Application Number


Associated Documentation

Application Form


PICO Confirmation

Final Protocol (PDF 585 KB)
Final Protocol (Word 6128 KB)

Assessment Report


Public Summary Document

Public Summary Document - November 2014 Update (PDF 273 KB)
Public Summary Document - November 2014 Update (Word 111 KB)

Meetings for this Application




12 to 13 June 2014


3 October 2014
26 to 28 November 2014